Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Clinical Trials Using Ulixertinib

Review the clinical trials studying ulixertinib on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 1-5 of 5

Ulixertinib for the Treatment of Patients with Relapsed or Refractory Histiocytic Neoplasms
Status: Active
Location: 8 locations
Ulixertinib in Combination with Ruxolitinib for Treatment of Myelofibrosis
Status: Active
Location: 7 locations
Ulixertinib and Palbociclib in Treating Patients with Advanced or Refractory Solid Tumors or Metastatic Pancreatic Cancer or Metastatic Melanoma
Status: Active
Location: UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina
Ulixertinib and Cetuximab or Ulixertinib, Cetuximab, and Encorafenib for the Treatment of Unresectable or Metastatic Colorectal Cancer in Patients Who Have Received EGFR or BRAF-Directed Therapy
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Ulixertinib for the Treatment of Recurrent Mitogen-Activated Protein Kinase Activated Glioma
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas